Oct 7, 2026 8:48am EDT Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
Sep 23, 2026 7:33am EDT Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
